866-997-4948(US-Canada Toll Free)

House Dust Mite Allergy - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 47 Pages

House Dust Mite Allergy - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2018, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 4 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy - Overview
House Dust Mite Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergy Therapeutics Plc
Anergis SA
ASIT Biotech SA
Biomay AG
Genetic Immunity Inc
Stallergenes Greer plc
Zhejiang I-Biological Technology Co Ltd
House Dust Mite Allergy - Drug Profiles
AllerDM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DermAll-HDM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hdm-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
House Dust Mite Allergy - Dormant Projects
House Dust Mite Allergy - Discontinued Products
House Dust Mite Allergy - Product Development Milestones
Featured News & Press Releases
Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US
Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France
Nov 23, 2017: European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ Allergy Immunotherapy Product Candidates
Oct 24, 2017: ASIT biotech Publishes the Results of The hdm-ASIT+ Phase I/II Follow-up Study in House Dust Mite Rhinitis
Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval
Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada
Aug 16, 2017: ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT Product Candidate for House Dust Mite Rhinitis
Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy
May 04, 2017: ALK's HDM SLIT-tablet, ACARIZAX, approved in Canada
Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
Mar 28, 2017: Shionogi Submits New Drug Application in Japan of S-524101 for Allergen Immunotherapy Treatment of Pediatric Allergic Rhinitis by House Dust Mite
Mar 01, 2017: FDA approves Odactra for house dust mite allergies
Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval
Jan 27, 2017: Stallergenes Greer Announces Positive Top-Line Results Of Phase 3 Study For Pediatric House Dust Mite-Induced Allergic Rhinitis
Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for House Dust Mite Allergy, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
House Dust Mite Allergy - Pipeline by ALK-Abello AS, H1 2018
House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H1 2018
House Dust Mite Allergy - Pipeline by Anergis SA, H1 2018
House Dust Mite Allergy - Pipeline by ASIT Biotech SA, H1 2018
House Dust Mite Allergy - Pipeline by Biomay AG, H1 2018
House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, H1 2018
House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H1 2018
House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2018
House Dust Mite Allergy - Dormant Projects, H1 2018
House Dust Mite Allergy - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for House Dust Mite Allergy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *